Eaton Corporation plc vs Sana Biotechnology Inc — how do they compare? Eaton Corporation plc trades at $395.57 (market cap $160.31B), while Sana Biotechnology Inc trades at $3.29 (market cap $987.94M). The key difference: Eaton Corporation plc is far larger — about 162.3× Sana Biotechnology Inc's market cap, and Eaton Corporation plc pays a 1.07% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| ETN | SANA | |
|---|---|---|
Market Cap | $160.31B | $987.94M |
Sector | Technology | Health |
52-Week High | $435.78 | $5.92 |
52-Week Low | $315.82 | $2.68 |
Enterprise Value | $181.40B | $962.13M |
Dividend Yield | 1.07% | — |
Signals from Pluang's Aura AI — not financial advice
Eaton Corporation (ETN) trades at $404.20, down 2.72% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.81 exceeding expectations. Analyst consensus is overwhelmingly positive with 25 buy ratings and a $449.50 price target. Recent news highlights growth in AI data center power infrastructure and a new sustainability report showing 40% emissions reduction.
ETN's outlook remains favorable due to robust demand in data center and aerospace markets, though elevated valuation multiples (P/E 40.4) pose a risk if growth moderates. The stock offers upside to consensus targets but faces execution risks from large 2026 investing outflows. Dividend payments provide income support with the next $1.10 distribution scheduled for May 29, 2026.
SANA Biotechnology trades at $3.45, down 3.36% today, with a bullish technical signal from moving averages and oscillators. The company shows strong analyst support with 82% buy ratings but faces significant financial challenges including negative ROE of -147.41% and consistent quarterly losses. Recent developments include positive clinical data presentations and a strategic collaboration with Mayo Clinic announced in May 2026.
While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial cash burn and negative profitability present significant investment risks. The stock's outlook depends heavily on successful clinical development and future revenue generation from its engineered cell therapies.
Trailing returns across standard periods
Latest headlines on both assets
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →